8-K: MapLight Therapeutics Reports Positive Phase 2 Schizophrenia Trial Results

MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, meeting its primary endpoint and showing a favorable safety profile.

Summary

• MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in adult patients with schizophrenia experiencing an acute exacerbation of psychosis.
• The trial met its primary endpoint, with the 210/3 mg twice-daily (BID) dose showing a statistically significant improvement in PANSS total score compared to placebo at Week 5 (effect size 0.37, p=0.015).
• A prespecified secondary endpoint showed a robust improvement in cognitive performance in participants with baseline cognitive impairment (effect size 0.51, p=0.041), independent of psychotic symptom improvement.
• Key secondary endpoints, including CGI-S and PANSS Positive Marder Factor, also showed significant improvement.
• ML-007C-MA was generally well-tolerated, with no serious or drug-related severe adverse events, low rates of gastrointestinal-related discontinuations, and no fasting requirement or complex titration.
• The company plans to engage with the FDA at an End-of-Phase 2 meeting to discuss the design of a confirmatory Phase 3 trial to support an initial New Drug Application (NDA) submission.
• The 330/6 mg once-daily (QD) dose showed numerical improvement but did not reach statistical significance on the primary endpoint.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with the trial meeting its primary endpoint and demonstrating a promising cognitive benefit and favorable safety profile, supporting advancement to Phase 3.

Positives

• The Phase 2 ZEPHYR trial met its primary endpoint, demonstrating a statistically significant improvement in PANSS total score for the 210/3 mg BID dose compared to placebo.
• A clinically meaningful improvement in cognitive performance was observed on a prespecified secondary endpoint, suggesting a potential differentiating factor.
• The drug candidate ML-007C-MA exhibited a favorable safety and tolerability profile, with no serious or drug-related severe adverse events.
• Low rates of gastrointestinal-related discontinuations and no need for fasting or complex titration are expected to improve real-world adherence.
• The 210/3 mg BID dose showed significant separation on key secondary endpoints, including CGI-S and PANSS Positive Marder Factor.
• The trial design was intended to support registration, and the results support proceeding with a confirmatory Phase 3 trial.
• The company plans to engage with the FDA for an End-of-Phase 2 meeting to discuss the path to an NDA submission.

Negatives

• The 330/6 mg once-daily (QD) dose did not achieve statistical significance on the primary endpoint, although it showed numerical improvement.
• While generally well-tolerated, treatment-emergent adverse events (TEAEs) were reported in 74.7% of participants on the 210/3 mg BID dose compared to 48.1% on placebo.
• Gastrointestinal events, though mostly mild, were present in the active treatment arms.
• The company is conducting further analyses to determine the potential path forward for a once-daily regimen.

Risks

• The company's product candidates are under preclinical and clinical study and have not yet been approved for marketing by the FDA.
• Forward-looking statements are subject to substantial known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.
• Risks described in the company's Form 10-Q and other SEC filings may impact future results.
• New risks may emerge, and the company's management cannot predict all risks or assess their impact.
• There is no guarantee that the company will achieve its plans, intentions, or expectations disclosed in forward-looking statements.
• Subsequent events and developments may cause the company's views to change, and there is no current intention to update forward-looking statements except as required by law.
• The company may not be able to secure regulatory approval for ML-007C-MA or other product candidates.
• The success of future clinical trials, including the planned confirmatory Phase 3 trial, is not guaranteed.

Future Outlook

The company plans to advance ML-007C-MA into a confirmatory Phase 3 trial to support an initial NDA submission, pending FDA feedback. They are also exploring other dosing regimens and indications, including Alzheimer's disease psychosis (VISTA trial) and potentially other neuropsychiatric disorders. Topline results for the VISTA trial are expected in the second half of 2027.

Management Comments

• We are very encouraged by these results, which show that ML-007C-MA delivered clinically meaningful antipsychotic efficacy alongside a favorable tolerability profile designed to translate into real-world use.
• Just as importantly, we observed a robust signal on a pre-specified secondary cognition endpoint that appears independent of antipsychotic effect.
• We believe the combination of a significant effect on PANSS and other concordant endpoints, along with a meaningful effect on cognitive performance, represents a powerful, comprehensive overall efficacy profile in schizophrenia, and strengthens the rationale for our ongoing VISTA trial in Alzheimers disease psychosis and the broader indication expansion for ML-007C-MA.
• The ZEPHYR results are notable on both fronts: a statistically significant improvement on the primary endpoint and cognitive performance, alongside a meaningfully differentiated safety profile that matters most for the management of patients over time.
• If confirmed in a further study and approved, ML-007C-MA could offer physicians a valuable additional tool in the treatment arsenal for people living with schizophrenia.

Industry Context

StockSavvy.ai notes that the positive results for ML-007C-MA in schizophrenia, particularly the observed cognitive benefits and favorable tolerability, align with the industry's ongoing efforts to develop more comprehensive treatments that address both core symptoms and cognitive deficits, which remain significant unmet needs in schizophrenia care. The drug's potential to offer a differentiated profile compared to existing antipsychotics and other investigational agents is a key factor in its potential market positioning.

Comparison to Industry Standards

• The effect size of 0.37 for ML-007C-MA on the PANSS Total Score in the mITT population falls within the range of approved antipsychotics, which typically show effect sizes between 0.26 and 0.63.
• The completer analysis effect size of 0.50 for ML-007C-MA is comparable to or stronger than some approved therapies like Cobenfy (estimated 0.50-0.56).
• The observed cognitive improvement (Effect Size 0.51) is notable, as demonstrating meaningful cognitive benefit in schizophrenia has been a significant challenge for many therapies.
• The tolerability profile, characterized by lower rates of moderate-to-severe TEAEs (26% for ML-007C-MA vs. 34-36% for Cobenfy's pivotal trials) and low GI-related discontinuations, appears to be a key differentiator compared to some existing treatments like Cobenfy, which has higher rates of GI TEAEs and discontinuations.
• The absence of a fasting requirement and a simple one-dose titration for ML-007C-MA contrasts with some other agents that may have more complex dosing or administration requirements.

Stakeholder Impact

• Shareholders: Positive trial results are likely to be viewed favorably, potentially impacting stock price and future investment.
• Patients with Schizophrenia: The potential for a new treatment option with efficacy in core symptoms and cognitive function, coupled with a favorable tolerability profile, could significantly improve patient outcomes and adherence.
• Clinicians: The data suggest ML-007C-MA could become a valuable tool in treating schizophrenia, offering a differentiated profile.
• Regulators (FDA): The results provide a basis for discussion regarding the path to regulatory approval, including the design of Phase 3 trials.

Next Steps

• Engage with the FDA at an End-of-Phase 2 meeting to discuss the path forward for ML-007C-MA in schizophrenia.
• Design and initiate a confirmatory Phase 3 trial for ML-007C-MA in schizophrenia, intended to support an initial NDA submission.
• Conduct further analyses to inform the potential path forward for a once-daily regimen of ML-007C-MA.
• Continue the VISTA trial evaluating ML-007C-MA for Alzheimer's disease psychosis, with topline results expected in 2H 2027.
• Engage with the FDA regarding the development of ML-004 for irritability associated with Autism Spectrum Disorder (ASD).

Key Dates

Recommendation

The results are positive and support advancement to Phase 3, but confirmation in larger trials and regulatory approval are still required. The stock may react positively, but further de-risking is needed before a stronger recommendation can be made.

Keywords

schizophrenia, ML-007C-MA, Phase 2 trial, ZEPHYR trial, MapLight Therapeutics, PANSS, cognitive impairment, muscarinic agonist